APA (7th ed.) Citation

M, S., J, d. l. C., I, G., RC, Á., P, G., DF, G., . . . A, M. (2025). Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: A randomised, clinical trial design. BMC cancer, 25(1), 1773. https://doi.org/10.1186/s12885-025-14620-z

Chicago Style (17th ed.) Citation

M, Salgado, et al. "Tinzaparin for the Prevention of Thromboembolic Events in Ambulatory Patients with Metastatic Colorectal Cancer Receiving First Line Treatment: A Randomised, Clinical Trial Design." BMC Cancer 25, no. 1 (2025): 1773. https://doi.org/10.1186/s12885-025-14620-z.

MLA (9th ed.) Citation

M, Salgado, et al. "Tinzaparin for the Prevention of Thromboembolic Events in Ambulatory Patients with Metastatic Colorectal Cancer Receiving First Line Treatment: A Randomised, Clinical Trial Design." BMC Cancer, vol. 25, no. 1, 2025, p. 1773, https://doi.org/10.1186/s12885-025-14620-z.